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Abstract
Patients with cancer frequently use dietary supplementation and herbal therapies to control symptoms of disease
and adverse effects of cancer therapy. Despite the widespread use of dietary supplementation and herbal
therapies in oncology, robust scientific evidence in this area is lacking. Not only do these products need to be
tested in large and well-designed observational or randomized studies, but their manufacturing process must be
improved to achieve higher levels of standardization in product quality. Ginger is frequently used to counteract
chemotherapy-induced nausea and vomiting (CINV), and some suggestions that it might be effective against
CINV come from randomized and/or crossover clinical trials. However, several limitations in the methods of
these studies limit their power and generalizability. The authors are conducting a randomized, double-blind
study with a large sample size and homogeneous inclusion criteria in order to evaluate the efficacy of a well-
standardized ginger extract in reducing nausea in patients with cancer. The widespread use of standardized
herbal therapies and natural components among patients requires that scientific and rigorous research strategies
are applied in this field to guide the physicians and the patients in safer use.
Introduction
The use of dietary supplementation and herbal thera-pies has become highly prevalent among patients with
cancer.1Up to 80%of cancer survivors take vitamin andmineral
supplements, and 14%–32% of patients begin using supple-
ments after they are diagnosedwith cancer.2 These interventions
may help control symptoms of disease and the adverse effects of
cancer therapy, such as nausea, vomiting, and oralmucositis.3 A
potential role of these interventions in the prevention of different
types of cancer has also been suggested; however, although
some isolated evidence led to promising results,4 at present their
use in the primary prevention of chronic diseases, including
cancer, cannot be recommended.5 In addition, the uncontrolled
use of these therapies may result in increased costs.6
Despite the widespread use of nutritional supplements
and herbal therapy in oncology, only a few of these inter-
vention have been evaluated with scientific research tools.7,8
A major gap exists between the current level of scientific
evidence and what is needed to provide robust, evidence-
based advice.7 Research is limited by a lack of sufficient
funding and qualified investigators, as well as by method-
ological and ethical issues. Therefore, ‘‘gaps in research are
the norm rather than the exception in this field,’’ according
to the Society for Integrative Oncology.7 The performance
of large and well-designed observational or randomized
studies—likely with the support of government institutions
or pharmaceutical companies—will identify well-grounded
evidence on the potential benefits and risks of these com-
plementary therapies, with substantial effects on personal
and clinical decision-making and policy-making.7,8
Nevertheless, to reduce the overall bias of clinical results,
it is of primary importance to improve product quality. This
methodological aspect is necessary for herbals, for which
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the relative concentration of active substances in each single
preparation can vary significantly, with direct variation of clin-
ical results. The results will therefore reflect this bias even if the
clinical trial is conducted according to large and well-designed
observational or randomized studies. Modern technologies to
standardized the product should therefore be used.9,10
Theuseof complementary treatment substances is particularly
intriguing in the prevention of adverse events due to oncologic
treatment. In this regard, chemotherapy-induced nausea and
vomiting (CINV) is one of the most distressing symptoms.11,12
This article discusses ginger as an example. Ginger (Zin-
giber officinale) has been used for centuries as a remedy for
many gastrointestinal conditions.13 Its use in this setting is
justified by its chemical properties. The rhizome of ginger
possesses an array of bioactive compounds, such as gingerols,
shogaols, zingiberene, zingerone, and paradol, that may stim-
ulate oral and gastric secretions, regulate gastrointestinal
motility, interact with the 5HT3 and NK1 receptors involved
in the CINV reflex, and act as a scavenger for free radicals.13
Common side effect are heartburns and dermatitis; sometimes
heartburn onset can be confused with nausea persistence.14
A recent systematic literature review15 identified seven
randomized and/or crossover trials of ginger versus placebo or
current antiemetic therapies in patients undergoing chemo-
therapy.16–22 The sample sizes of these studies ranged from36
to 576 patients, whowere receiving a variety of chemotherapy
regimens. The timeframe of CINV symptom assessment
varied among the studies from 3 days before chemotherapy
treatment to 10 days after treatment. Inmost cases, ginger was
supplied as encapsulated powder or standardized extracts
based on gingerol content. Dosing was 1–2 g per day over
1–10 days. Overall, three trials demonstrated the benefit of
ginger in themanagement of acute or delayed CINV,19–21 two
showed an effect similar to that of metoclopramide,17,18 and
two had unsatisfactory results.16,22 Moreover, the heteroge-
neity of ginger doses and formulations, and often the lack of
appropriate antiemetic treatment in the control group, limit
the applicability of these results to daily clinical practice.
Globally, suggestions that ginger might be effective
against CINV exist, but design inadequacies, heterogeneity
of the patient population, small numbers, and lack of dose-
finding studies limit the power of the trials and the possi-
bility to offer generalized results.
The authors have launched a randomized, double-blind,
placebo-controlled, clinical trial in six Italian centers with
two parallel groups of patients receiving at least two cycles of
highly emetogenic treatments (ClinicalTrials.gov identifier:
NCT01887314). The study was approved by the ethics
committee of the Istituto Nazionale Tumori and by the ethics
committees of all the other centers involved in the study. All
patients signed an informed consent form before inclusion in
the trial. The patients are randomly assigned to treatment with
160mg of ginger extract per day (Ginpax [Helsinn Healthcare
SA, Lugano, Switzerland], soft-gel capsules; ginger is grown
in China and then is submitted to a strict surveillance of each
batch of product with repeated analyses aimed at character-
izing the ingredients) or to placebo between day 2 of
cisplatin-based chemotherapy and the day before the next
cycle. All patients receive the standard prophylaxis against
cisplatin-induced acute (aprepitant, dexamethasone and a
5-HT3 antagonist) and delayed (aprepitant plus dexametha-
sone) emesis.
The primary objective of this study is to evaluate the
efficacy of a well-standardized ginger extract, containing a
fixed amount of gingerols and shogaols, in reducing delayed
nausea in patients with cancer over two cycles of highly
emetogenic treatments. In more detail, the main endpoint is
to evaluate the protection from delayed nausea; secondary
endpoints include overall duration and severity of nausea,
intercycle nausea, and nausea anticipatory symptoms. Safety
considerations will be taken, and the potential correlation of
treatment-emerging adverse events with the study product
will be assessed. On the basis of literature review, the
sample size was estimated to be 250 patients in order to
have a sample large enough to assess a difference of 15%
between the two treatment groups in the proportion of pa-
tients with no nausea. This large sample size, the strict and
homogeneous inclusion criteria, and the double-blind design
are the principal strengths of this study. Moreover, a trans-
lational part is foreseen, aimed at identifying the level of
serum inflammatory cytokines in a subgroup of patients.
Complementary and alternative medicines are largely
diffused throughout the world, and their use has rapidly
grown in recent years.1,2,16,17 However, not all these com-
pounds are harmless, and the perception of safe and holistic
treatment could expose patients to uncontrolled use.
Because of the widespread use of standardized herbal
therapies and natural components among patients, scientific
and rigorous research strategies are necessary. Also needed
is knowledge of the benefits and possible harms or inter-
actions of complementary medicine in supportive care. The
scientific method should be maintained consistently in this
field in order to provide evidence-based recommendations
that can guide physicians and patients in safer use and make
them aware of the real benefit of these agents, their potential
interactions with other drugs, and adverse events.
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